Comparing Botox® and Xeomin® for axillar hyperhidrosis

Journal of Neural Transmission

Volumn 117, Issue 3, 2010, Pages 317-319

  Dressler, Dirk ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adverse effect profile; Botulinum toxin type a; Complexing proteins; Hyperhidrosis; Therapeutic effect

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; HENGLI; MYOBLOCK; UNCLASSIFIED DRUG; BOTULINUM TOXIN; NEUROTOXIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; AXILLA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSAGE FORM COMPARISON; FEMALE; HUMAN; HYPERHIDROSIS; INJECTION SITE PAIN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; COMPARATIVE STUDY; TIME; TREATMENT OUTCOME;

ADULT; AXILLA; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; FEMALE; HUMANS; HYPERHIDROSIS; MALE; NEUROTOXINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952423378     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-010-0372-0     Document Type: Article

References (8)

1. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949-1951. (Pubitemid 40800714)
2. Dressier D (2006) Pharmakologische Aspekte der Botulinum Toxine. Nervenarzt 77:912-921
3. Dressler D, Adib Saberi F, Benecke R (2002) Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 249:1729-1732 (Pubitemid 36269268)
4. Dressler D, Mander G, Fink K (2008) Equivalent potency of Xeomin®and Botox®. Mov Disord 23(Suppl 1):S20-S21
5. Friday D, Bigalke H, Frevert J (2002) In vitro stability of botulinum toxin complex at physiological pH and temperature. Naunyn Schmideberg's Arch Pharmacol 365(Suppl 2):46
6. Naumann M, Flachenecker P, Bröcker EB, Toyka KV, Reiners K (1997) Botulinum toxin for palmar hyperhidrosis. Lancet 349(9047):252
7. Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS, Jabbari B, Kaufmann HC, Schurch B, Silberstein SD, Simpson DM, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2008) Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70:1707-1.714 (Pubitemid 351644139)
8. Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S (2006) Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113:303-312 (Pubitemid 43201097)